345 related articles for article (PubMed ID: 30982556)
1. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A
Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556
[TBL] [Abstract][Full Text] [Related]
2. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
[TBL] [Abstract][Full Text] [Related]
3. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
[TBL] [Abstract][Full Text] [Related]
5. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
8. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
9. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.
Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A
Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620
[TBL] [Abstract][Full Text] [Related]
12. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
[TBL] [Abstract][Full Text] [Related]
13. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
Luxembourg A; Moeller E
Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
[TBL] [Abstract][Full Text] [Related]
14. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.
Signorelli C; Odone A; Ciorba V; Cella P; Audisio RA; Lombardi A; Mariani L; Mennini FS; Pecorelli S; Rezza G; Zuccotti GV; Peracino A
Epidemiol Infect; 2017 Jul; 145(10):1962-1982. PubMed ID: 28446260
[TBL] [Abstract][Full Text] [Related]
17. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
Castellsagué X; Muñoz N; Pitisuttithum P; Ferris D; Monsonego J; Ault K; Luna J; Myers E; Mallary S; Bautista OM; Bryan J; Vuocolo S; Haupt RM; Saah A
Br J Cancer; 2011 Jun; 105(1):28-37. PubMed ID: 21629249
[TBL] [Abstract][Full Text] [Related]
18. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
19. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
FUTURE II Study Group
J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
